



## **FSD PHARMA BREAKS ALL-TIME MONTHLY STOCK VOLUME TRADING RECORD**

**/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE US/**

CSE: HUGE

TORONTO, July 5, 2018 /CNW/ – FSD Pharma Inc. (“FSD” or the “Company”) (CSE:HUGE), is pleased to report that in the one month period of trading between May 29, 2018 and June 28, 2018, the company traded exactly 869,232,894 Class B subordinate voting shares on the Canadian Securities Exchange (“CSE”). This is the largest total quantity of share volume ever traded by a CSE listed issuer within a one month period of consecutive days of trading. Comparatively, the largest amount traded prior on the CSE in a one month period of consecutive days was 380,976,411. This is a new record as confirmed by the CSE.

The company wishes to again thank all its shareholders and stakeholders for their support to date, which has resulted in yet another record-breaking achievement in the Canadian cannabis investment marketplace.

### **About FSD Pharma Inc. (CSE:HUGE)**

FSD Pharma, owns, through its wholly-owned subsidiary FV Pharma Inc., a license to produce marijuana under the Access to Cannabis for Medical Purposes Regulations (ACMPR) which was originally granted on October 13, 2017. Headquartered at the former Kraft plant in Cobourg, Ontario, approximately an hour’s drive from Toronto, FSD Pharma’s management’s mission is to transform the facility into the largest hydroponic indoor cannabis facility in the world. FSD Pharma intends to target all legal aspects of the cannabis industry, including cultivation, processing, manufacturing, extracts and research and development. Please visit [www.fsdpharma.com](http://www.fsdpharma.com) for more information.

### **Forward-Looking Information**

***Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Corporation’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the development of the Corporation’s indoor cannabis facility and its business goals and objectives. The forward-looking information contained in this press release is made as of the date hereof, and the Corporation is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions***

***contained herein, investors should not place undue reliance on forward looking-information. The foregoing statements expressly qualify any forward-looking information contained herein.***

**Anthony Durkacz**

Director, FSD Pharma Inc.

[anthony@firstrepubliccapital.com](mailto:anthony@firstrepubliccapital.com)

416-720-4360

SOURCE FSD Pharma Inc.

For further information: Investor Relations, Phone: 416-433-2166, Email: [IR@fsdpharma.com](mailto:IR@fsdpharma.com),  
Website: [www.fsdpharma.com](http://www.fsdpharma.com)